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AB S T R A CT  
The Simpson-Golabi-Behmel Syndrome (SGBS) or overgrowth Syndrome is an uncommon genetic X-
linked disorder highlighted by macrosomia, renal defects, cardiac weaknesses and skeletal 
abnormalities. The purpose of the work was to classify the functional nsSNPs of GPC3 to serve as 
genetic biomarkers for overgrowth syndrome. The raw data of GPC3 gene were retrieved from dbSNP 
database and used to examine the most damaging effect using eight functional analysis tools, while we 
used I-mutant and MUPro to examine the effect of SNPs on GPC3 protein structure; The 3D structure 
of GPC3 protein is not found in the PDB, so RaptorX was used to create a 3D structural prototype to 
visualize the amino acids alterations by UCSF Chimera; For biophysical validation we used project 
HOPE; Lastly we run conservational analysis by BioEdit and Consurf web server respectively. Our 
results revealed three novel missense mutations (rs1460413167, rs1295603457 and rs757475450) that 
are that are more likely to be responsible for disturbance in the function and structure of GPC3. This 
work provides new insight into the molecular basis of overgrowth Syndrome by evidence from 
bioinformatics analysis. Three novel missense mutations (rs757475450, rs1295603457 and 
rs1460413167) are more likely to be responsible for disturbance in the function and structure of GPC3; 
therefore, they may be assisting as genetic biomarkers for overgrowth syndrome. As well as these SNPs 
can be used for the larger population-based studies of overgrowth syndrome. 
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1 Introduction 
The Simpson-Golabi-Behmel Syndrome (SGBS) 
or Overgrowth Syndrome is an uncommon 
genetic disorder characterized by macrosomia, 
renal defects, cardiac weaknesses and skeletal 
abnormalities.[1-4] the first case was reported 
around 1940.[5] So far, two unlike types of 
overgrowth Syndrome have been defined. The 
typical SBGS type one [2-8] and a fatal and rare 
system, possibly 10 conditions defined known as 
SGBS type two.[9-11] Furthermore, these cases 
could rapidly develop Wilms’ malignancy.[12] 
Early passing is more common.[13] Different 
mutations have been described in SGBS type 
one.[14-22] 
Overgrowth Syndrome caused by mutations in 
glypican 3 (GPC3) gene is localized on Xq26.1 
[23, 24] which encrypts glypican-3. [17, 19, 20, 
25-29] that seemingly acting a bad part in growth 
control by an anonymous fate, However, 
outcomes from an exhaustive qualified study of 
growth forms in dual mutants missing 
GPC3 provided conclusive genetic evidence 
inconsistent with the theory that GPC3 
performances as a growth suppressor.[29] Such a 
proteoglycan is contingent to show a vital part in 
regulate and diagnosis in mesodermal tissues and 
in tumors predisposition.[30, 31] Some studies 
show association between GPC3 gene and some 
types of human cancers.[32-36]   
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The aim of this work was to detect the most 
deleterious SNPs in GPC3 that may cause 
overgrowth Syndrome type one by using of 
different bioinformatics tools, Furthermore and 
to be used as genetic biomarkers. nsSNP is an 
alteration that occurs in a single base pair of 
amino acid which leads to disturb or change the 
corresponding protein’s function, if the second 
possibility happened, it may cause a severe 
phenotypic impact and in return responsible for 
the pathology of the disease [37, 38] Clinical 
testing for deleterious SNPs frequently discloses 
alterations that are not easily considered as 
deleterious, for that reason a great effort has been 
done by translational bioinformatics tools for 
analysis of nsSNPs which have improved 
significantly in recent years and thus become 
more reliable for SNPs analysis.[39] Translational 
analysis has been considered as an essential 
science in the field of personalized medicine 
which aims to fill the gap between clinical and 
academic research by prioritizing the most 
pathogenic nsSNPs for further studies.[40-44] 
This is the first computational analysis of GPC3 
gene that classify nsSNPs for the larger 
population-based studies of overgrowth 
syndrome. 
2 Methods 
2.1 Data Mining 
The raw data of GPC3 gene were retrieved from 
National Center for Biotechnology Information 
(NCBI) website.[45, 46] The reference sequence 
of the protein was retrieved from Uniprot 
database.[47] 
2.2 Functional Analysis 
2.2.1 SIFT 
It is the first functional analysis online tool which 
designed to predict whether a SNP is damaging 
or not by specific algorithm have a score <0.05 
are predicted to be damaging SNP, otherwise it 
reflected to be not damaging.[48, 49] 
2.2.2 PolyPhen 
It is a functional analysis online tool to examine 
potential influences of a SNP on functional and 
structural characteristics of our protein of 
interest.[50, 51] 
2.2.3 PROVEAN 
It is a functional analysis online tool which we 
used to calculate if a SNP has an impression on 
the physical role of our protein of interest. 
PROVEAN probability has two possibilities, 
deleterious or neutral with cutoff -2.5.[52] 
2.2.4 SNAP  
It is a functional analysis tool with an artificial 
intelligence machine device called "neural 
network"; It distinguishes between effect and 
neutral variants/non-synonymous SNPs by 
taking a variety of sequence and variant features 
into account. [53, 54] 
2.2.5 SNPs&GO 
It is a functional analysis tool which distinguishes 
between the damaging SNPs from the neutral 
ones. The other methods were used too (PHD-
SNP and PANTHER).[55, 56]  
2.2.6 P-Mut 
It is an online functional analysis tool for the 
clarification of amino acid alternates on proteins, 
permits the swift and accurate intention (80%) of 
the obsessive characteristics of each SNP 
stranded on the preparation of neural 
systems.[57, 58] 
2.3 Stability Analysis 
2.3.1 I-Mutant 3.0 
It is SVM-based (Support Vector Machine) tool 
for the automatic prediction of protein stability 
changes upon single point mutations. The 
predictions are performed starting either from 
the protein structure or, more importantly, from 
the protein sequence.[59, 60] 
2.3.2 MUPro 
It is an online tool we used; it runs by the same 
concept of I-Mutant 3.0 but it’s more accurate 
than I-Mutant 3.0 by 84.2%.[61, 62] 
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2.4 Biophysical and Visualization 
Analysis 
2.4.1 Project Hope 
It is an online web-server for biophysical 
validation which brings together a series of 
related protein data to form a model if there are 
enough 3D structural data; also to run this data 
to predict if the amino acid alteration may affect 
in the protein function or not.[63] 
2.4.2 RaptorX 
The 3D structure of the protein of GPC3 it is not 
found at protein data bank (PDB), so RaptorX 
was used to perform a 3D structure model for 
GPC3 protein.[64, 65] 
2.4.3 UCSF Chimera 
It is a visualization analysis program of 3D 
structure model, docking analysis and so many 
related analyses; the predicted model was used to 
visualize and compare the amino acid alterations 
by UCSF Chimera [66, 67]. 
2.5 Conservational Analysis 
2.5.1 BioEdit 
It is a program package created to stream a 
distinct program that can run approximately any 
sequences operation, demonstrating, as well as a 
few basic alignment studies.[68] 
2.5.2 ConSurf Server 
It is proposing evolutionary conservation 
outlines for proteins of known structure in the 
PDB. ConSurf red flag the similar amino acid 
sequences and run multi alignment approaches. 
The conserved regions of amino acids identify its 
site by using particular system.[69, 70] 
3 Results 
The effect of each SNP has been studied 
regarding to function and stability of the protein 
by different computational analysis tools with 
different considerations and features, in order to 
decrease the error to the lowest ratio possible 
(Figure 1). 
 
Figure 1: Illustrative Workflow used for SNPs analysis 
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Table 1: Affecting protein function mutations predicted by several online tools: 
dbSNP rs# sub SIFT 
Prediction 
Score Polyphen 
Prediction  
Score PROVEAN 
Prediction  
Score SNAP2 
Prediction  
Score 
- D500Y Deleterious 0  Damaging 1 Deleterious -4.572 Deleterious 68 
rs1203009272 G440R Deleterious 0  Damaging 1 Deleterious -5.147 Deleterious 90 
rs104894854 W296R Deleterious 0  Damaging 1 Deleterious -
13.836 
Deleterious 98 
rs1460413167 P212H Deleterious 0  Damaging 1 Deleterious -7.77 Deleterious 73 
rs140848049 F208L Deleterious 0 Damaging 1 Deleterious -5.913 Deleterious 78 
rs1295603457 C65Y Deleterious 0  Damaging 1 Deleterious -7.572 Deleterious 87 
rs757475450 R39C Deleterious 0 Damaging 1 Deleterious -4.575 Deleterious 59 
*Sub: Substitutions 
Table 2: Disease related nsSNPs predicted by several online tools 
sub SNPs&GO 
Prediction 
RI Probability PANTHER 
Prediction 
RI Probability PHD-SNP 
Prediction 
RI Probability P-mut 
Prediction 
Probability 
W296R Disease 7 0.858 Disease 10 0.99 Disease 9 0.925 Disease 0.89 (92%) 
P212H Disease 4 0.709 Disease 10 0.994 Disease 6 0.788 Disease 0.81 (89%) 
C65Y Disease 6 0.787 Disease 8 0.878 Disease 7 0.85 Disease 0.80 (89%) 
R39C Disease 3 0.63 Disease 8 0.903 Disease 4 0.687 Disease 0.73 (87%) 
*RI: Reliability Index 
Table 3: Structural investigation expected by I-mutant and MUPro: 
dbSNP rs# Substitutions SVM Prediction 
Effect 
RI Prediction MUPro 
Prediction  
Score 
rs104894854 W296R Decrease 8 -0.99 Decrease -0.95856 
rs1460413167 P212H Decrease 8 -1.67 Decrease -1.30249 
rs1295603457 C65Y Increase 0 -0.09 Decrease -0.56309 
rs757475450 R39C Decrease 3 -0.74 Decrease -0.28424 
 
The total number of SNPs regarding to GPC3 
gene is 765 SNPs, out of 256 nsSNPs 
were submitted to SIFT, PolyPhen-2, 
PROVEAN and SNAP2 respectively. SIFT 
predicted 109 damaging mutations, PolyPhen-2 
predicted 115 deleterious mutations (50 possibly 
damaging (less confident prediction) and 65 
probably damaging (more confident prediction)), 
PROVEAN predicted 82 deleterious mutations 
and SNAP2 predicted 127 damaging mutations. 
Once we filtered the four positive deleterious 
mutations, the number of SNPs reduced to 7. 
(Table 1) after that, the same 7 mutations were 
submitted to SNPs&GO, PHD-SNP, 
PANTHER and P-Mut for further study to 
examine their influence on the function of GPC3; 
7 deleterious mutations were predicted by PHD-
SNP and P-mut, SNP&GO predicted 5, while 
PANTHER predicted 5 deleterious mutations. 
Once we filtered the four positive deleterious 
mutations the number reduced to 4 SNPs (Table 
2) after that, we submitted them to I-Mutant and 
MUPro to investigate their effect on the stability; 
The two online tools revealed that, All the 
mutations decreased the protein stability, except 
for one SNP (G257D) was predicted by I-Mutant 
to increase the stability of the protein (Table 3). 
4 Discussion 
A significant interest in Homo sapiens genome has 
been focused to classify the deleterious SNPs; 
those are more likely to be responsible for 
inherited disorders. Therefore, a good effort was 
dictated to identify the most deleterious SNPs 
that may cause overgrowth syndrome. Our 
analysis revealed three novel SNPs in GPC3gene 
which were classified as highly deleterious SNPs, 
which as crucial impact at the functional level of 
the GPC3 gene, our analysis based on different 
sequence and structure-based algorithms, Figure 
(1). 
There is a study that has been reported which 
shows a missense mutation that causes 
overgrowth syndrome; [19]  which matches with 
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this study findings. Some studies show 
association between GPC3 gene and some types 
of liver cancer such as hepatocellular 
carcinoma.[30, 34, 71, 72]  Therefore, this study 
can open the door for novel diagnostic 
biomarkers for hepatocellular carcinoma. 
Combination detection of serum GPC3 and 
pathogenic SNPs through clinical and genetic 
testing must be positively matched; this can 
enhance accuracy and efficiency of hepatocellular 
carcinoma diagnosis. In addition it confirms that 
(W296R) is pathogenic; this result matches with 
the result found previously in dbSNPs database. 
Furthermore, these mutations (P212H, C65Y, 
R39C) were recovered as untested, in this study 
were found to be all pathogenic. 
At the functional level analysis, our results 
showed that all these nsSNPs substitutions 
(D500Y, G440R, W296R, P212H, F208L, C65Y, 
and R39C) were classified as likely pathogenic 
mutations, Table (1) the prediction efficacy has 
been increased by integrating the results of SIFT, 
PolyPhen-2, PROVEAN and SNAP2 based 
approaches, by combining the predictions of 
SNPs&GO, PhD-SNP, PANTHER, and P-Mut, 
Table (2) the output showed that all these 
nsSNPs (W296R, P212H, C65Y and R39C) are 
classified as highly pathogenic mutations. 
Therefore, our functional analysis suggested that 
these four nsSNPs might disrupt both the protein 
function and structure; while at the structural 
level analysis, MUPro results showed a decrease 
in stability for All these SNPs (W296R, P212H, 
C65Y and R39C) while I-Mutant results showed 
a decrease in stability for these SNPs (W296R, 
P212H and R39C), thus suggesting that these 
mutations could directly or indirectly destabilize 
the amino acid interactions triggering functional 
deviations of protein to some point. Table (3) 
The most four deleterious SNPs were submitted 
to project HOPE which shown that all they are 
located in a domain of GPC3 protein; therefore, 
they may have a dynamic alteration in the protein 
function; In (Figure 2): (R39C): Shows the 
schematic structures of the original amino acid 
(in the left) which is Arginine and the mutant one 
(in the right) which is Cysteine. The backbone, 
which is the same for each amino acid, is colored 
red (in the green and red boxes) and the side 
chain, unique for each amino acid, is colored 
black. In addition, figure shows Close-up angle of 
the mutation. The protein is colored white, wide 
type residue colored green and mutant one 
colored red in position 39. The mutant residue is 
smaller than the wild-type residue; the wild-type 
residue charge was positive, while the mutant 
residue charge is neutral, this can cause loss of 
interactions with other molecules or residues; the 
mutant residue is more hydrophobic than the 
wild-type residue, and this can result in loss of 
hydrogen bonds and/or disturb correct folding. 
 
Figure 2: (rs757475450) (R39C) Arginine changes 
to Cysteine at position 39; illustrated by chimera (v 
1.8) and project HOPE. 
Figure 3: (rs1295603457): (C65Y) Cysteine 
changes to Tyrosine at position 65; illustrated by 
chimera (v 1.8) and project HOPE. 
In (Figure 3): (C65Y): Shows the schematic 
structures of the original amino acid (in the left) 
which is Cysteine and the mutant one (in the 
right) which is Tyrosine. The backbone, which is 
the same for each amino acid, is colored red (in 
 6 
 
 ISSN: 2456-7132  
Available online at Journals.aijr.in 
Identification of Novel Key Biomarkers in Simpson-Golabi-Behmel Syndrome (SGBS) 
the green and red boxes) and the side chain, 
unique for each amino acid, is colored black. In 
addition, figure shows Close-up angle of the 
mutation. The protein is colored white, wide type 
residue colored green and mutant one colored 
red in position 65. The wild-type and mutant 
amino acids differ in size; the mutant residue is 
bigger, this might lead to bumps; the 
hydrophobicity of the wild-type and mutant 
residue differs; hydrophobic interactions, either 
in the core of the protein or on the surface, will 
be lost. 
Figure 4: (rs1460413167): (P212H) Proline 
changes to Histidine at position 212; illustrated by 
chimera (v 1.8) and project HOPE. 
In (Figure 4): (P212H): Shows the schematic 
structures of the original amino acid (in the left) 
which is Proline and the mutant one (in the right) 
which is Histidine. The backbone, which is the 
same for each amino acid, is colored red (in the 
green and red boxes) and the side chain, unique 
for each amino acid, is colored black. In addition, 
figure shows Close-up angle of the mutation. The 
protein is colored white, wide type residue 
colored green and mutant one colored red in 
position 212. The mutant residue is bigger, this 
might lead to bumps. The hydrophobicity of the 
wild-type and mutant residue differs; 
hydrophobic interactions, either in the core of 
the protein or on the surface, will be lost. Prolines 
are known to have a very rigid structure, 
sometimes forcing the backbone in a specific 
conformation. Possibly, this mutation changes a 
proline with such a function into another residue 
(Histidine), thereby disturbing the structure. 
In (Figure 5): (W296R): Shows the schematic 
structures of the original amino acid (in the left) 
which is Tryptophan and the mutant one (in the 
right) which is Arginine. The backbone, which is 
the same for each amino acid, is colored red (in 
the green and red boxes) and the side chain, 
unique for each amino acid, is colored black. In 
addition, figure shows Close-up angle of the 
mutation. The protein is colored white, wide type 
residue colored green and mutant one colored 
red in position 296.  
 
Figure 5: (rs104894854): (W296R) Tryptophan 
changes to Arginine at position 296; illustrated by 
chimera (v1.8) and project HOPE. 
The wild-type residue charge was neutral, the 
mutant residue charge is positive, the mutation 
introduces a charge, and this can cause repulsion 
of ligands or other residues with the same charge; 
the wild-type and mutant amino acids differ in 
size, and the mutant residue is smaller, this might 
lead to loss of interactions; The hydrophobicity 
of the wild-type and mutant residue differs, 
hydrophobic interactions, either in the core of 
the protein or on the surface, will be lost. 
We also observed that, all the four SNPs were 
located in conserve region. We believe that amino 
acids conserved across species are playing a 
crucial role at the functional level; therefore, the 
four SNPs that we have detected are more 
probable disease causing ones; (Figure 6) The 
same results were confirmed by ConSurf, which 
show the nsSNPs that they are located at 
extremely conserved sites; therefore, we have 
confidence that these SNPs have a tendency to 
7 
 
 ISSN: 2456-7132  
Available online at Journals.aijr.in 
Mustafa et al., Int. Ann. Sci.; Vol. 8, Issue 1, pp: 1-11, 2020 
be the most deleterious SNPs that may cause 
overgrowth syndrome. (Figure 7) 
This study is the first computational approach 
while all other earlier studies were in vitro, in vivo 
and whole exome sequencing. [73-76] It revealed 
three novel missense mutations that are more 
likely to be responsible for disturbance in the 
function and structure of GPC3; therefore, they 
could be used as diagnostic markers to Predict 
overgrowth syndrome.[77]  Lastly, some 
appreciations of wet lab techniques are suggested 
to support our in silico analysis findings. 
 
 
 
 
 
 
Figure 6: GPC3 Family of seven protein sequences representing that, the normal amino acids are 
expected to be altered (showed by red arrows) are evolutionarily conserved across species. 
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Figure 7: Shows the conserved amino acids across species in GPC3 protein were determined using Consurf.  
(e) An exposed residue according to the neural-network algorithm via an orange letter.  
(b) Residues predicted to be buried are demonstrated via a green letter.  
(f) A predicted functional residue (highly conserved and exposed) are indicated with a red letter.  
(s) A predicted structural residue (highly conserved and buried) that are demonstrated with a blue letter. 
 (I) Insufficient data- the calculation for this site was performed on less than 10% of the sequences are 
demonstrated via a yellow letter. 
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5 Conclusion 
Functional and structural impact of SNPs in the 
GPC3 gene was found out by using 
computational prediction tools; Out of a total of 
765 SNPs in the GPC3 gene, 256 were nsSNPs; 
out of 256 missense nsSNPs, 4 were found to be 
the most deleterious nsSNPs (three of them were 
novel R39C (rs757475450), C65Y 
(rs1295603457), and P212H (rs1460413167)) by 
eight functional analysis tools. Stability analysis 
results showed that the amino acid residue 
substitutions which had the greatest impact on 
the stability of the GPC3 protein were mutations 
R39C (rs757475450), C65Y (rs1295603457), 
P212H (rs1460413167) and W296R 
(rs104894854). This result helped us to 
characterize the impact of nsSNPs on GPC3 gene 
and should be considered important candidates 
in causing of overgrowth syndrome. 
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